Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure

Table 2

Baseline demographic, clinical, and laboratory characteristics of HB-ACLF survivors and nonsurvivors in the validated set.

	Total	Survivors	Nonsurvivors
Number	167	103	64
Age (yr)	43 (19-69)	40 (19-69)	44.5 (24-66)	0.155
Sex, male (, %)	140 (83.8)	86 (83.5)	54 (84.3)	0.881
HBeAg positive (n, %)	74 (44.3)	46 (44.7)	28 (43.8)	0.908
HBV-DNA (lg copies/ml)	5.93 (1.15-9.82)	5.82 (1.70-9.82)	6.10 (1.15-9.43)	0.376
Serum bilirubin (mg/dl)	20.19 (6.49-73.01)	17.85 (6.49-73.01)	22.69 (10.08-54.42)	0.001
Serum albumin (g/l)	30 (17-45)	31 (19-45)	29 (17-42)	0.167
ALT (U/ml)	549 (21-4747)	537 (21-4747)	578 (29-3742)	0.603
AST (U/ml)	335 (28-4202)	320 (49-4202)	365 (28-2598)	0.799
INR	2.22 (1.30-14.58)	2.07 (1.30-4.19)	2.95 (1.55-14.58)	≤0.001
Baseline sCr (mg/dl)	67 (33-378)	66 (38-221)	68 (33-378)	0.653
Leukocyte count (10^9/l)	7.46 (2.39-22.34)	6.87 (2.87-15.6)	8.29 (2.39-22.34)	0.016
Platelet count (10^9/l)	108 (30-246)	108 (30-211)	111.5 (33-246)	0.824
MELD score	24 (16-50)	23 (16-32)	27.5 (16-50)	≤0.001
CLIF-C OF	10 (6-16)	9 (6-12)	11 (8-16)	≤0.001
CRP (ng/ml)	10.9 (0.65-138.00)	10.5 (2.3-138)	12.08 (0.65-137)	0.979
PCT (ng/ml)	0.63 (0.16-34.99)	0.64 (0.24-2.35)	0.70 (0.16-34.99)	0.184
SuPAR (ng/ml)	10.75 (1.18-121.76)	7.85 (1.18-65.38)	19.8 (1.36-121.76)	≤0.001
Complications (, %)
Infection	108 (64.7)	57 (55.3)	51 (79.7)	0.001
Gastrointestinal bleeding	18 (10.8)	7 (6.8)	11 (17.2)	0.035
Hepatic encephalopathy	63 (37.7)	14 (13.6)	49 (76.6)	≤0.001
HRS	13 (7.8)	2 (1.9)	11 (17.2)	0.001

: number; yr: year; sCr: serum creatinine; MELD: model for end-stage liver disease; CLIF-C OF: chronic liver failure consortium organ failure; CRP: C-reactive protein; PCT: procalcitonin; HRS: hepatorenal syndrome.